[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100139870":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"French Cardiology Society","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with HCM",null,"Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Albert Hagege","CONTACT","33(0)156092897","albert.hagege@egp.ap-hop-paris.fr",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"European Georges Pompidou Hospital","RECRUITING","Paris","75015","France","FR",{"type":27,"coordinates":28},"Point",[29,30],2.3488,48.85341,{"lat":30,"lon":29},[33,35],{"name":14,"role":15,"phone":34,"phoneExt":10,"email":17},"33(0)156093683",{"name":14,"role":36,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Hagege Albert","Professor","100139870","french-hypertrophic-cardiomyopathy-observatory-100139870",false,"NCT01091480","French Hypertrophic Cardiomyopathy Observatory","REMY","Inclusion Criteria:\n\n* Age ≥ 15 years old\n* Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic\n\nExclusion Criteria:\n\n* Expressed refusal to participate in the study\n* Significant aortic stenosis (\\\u003C1 cm ²)","ALL","15 Years",{"count":50,"type":51},600,"ESTIMATED","OBSERVATIONAL","Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.\n\nThe purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)",[55],"Hypertrophic Cardiomyopathy",[57,58,59],"Hypertrophic cardiomyopathy","Observatory","LVH","2022-09-20",{"date":62,"type":63},"2022-09-21","ACTUAL",{"date":65,"type":63},"2010-01",{"date":67,"type":51},"2028-12",{"name":5,"class":6},1]